ETL Inhibitors are defined by their ability to indirectly influence the activity of ETL (ELTD1 - EGF-like repeats and discoidin I-like domains 1), a protein known for its involvement in angiogenic processes. While direct inhibitors targeting ETL specifically are not prominently recognized in the field of biochemistry and pharmacology, this class encompasses a range of compounds that modulate key signaling pathways indirectly associated with ETL's function. The primary action of these inhibitors is centered on pathways that regulate angiogenesis, a process in which ETL is implicated. The chemical structures of ETL inhibitors vary significantly, as they are not unified by a common target but rather by their collective ability to modulate the angiogenic landscape in which ETL operates. This includes inhibition of tyrosine kinases, growth factor receptors, and other enzymes pivotal in the signaling cascades that govern angiogenic activity.
The functional focus of ETL inhibitors lies in their interaction with molecular pathways crucial for the development and maintenance of angiogenic processes. This includes targeting vascular endothelial growth factor receptors (VEGFR), epidermal growth factor receptor (EGFR), and multiple kinases that are instrumental in cellular signaling related to angiogenesis. By modulating these pathways, ETL inhibitors indirectly impact the environment and regulatory networks in which ETL functions. The range of targets these inhibitors interact with reflects the complexity of angiogenesis as a biological process, involving an array of signaling molecules and cellular interactions. The diversity in their mechanisms of action demonstrates the multifaceted approach required to influence a process as intricate as angiogenesis, where ETL plays a role. The effectiveness of these inhibitors is gauged by their ability to modulate the signaling cascades and molecular interactions that form the basis of angiogenic activity, indirectly affecting the functional dynamics of ETL within this context.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A tyrosine kinase inhibitor, potentially impacting ELTD1 activity by inhibiting angiogenic signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases involved in angiogenesis, could indirectly modulate ELTD1 function. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Another tyrosine kinase inhibitor that may indirectly affect ELTD1 through its anti-angiogenic activity. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Primarily an EGFR inhibitor, might indirectly impact angiogenesis and ELTD1 activity. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
A multikinase inhibitor that could indirectly influence ELTD1 through anti-angiogenic properties. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits VEGFR and other kinases, potentially affecting angiogenic pathways involving ELTD1. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and other kinases, potentially influencing ELTD1 activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Primarily targets BCR-ABL tyrosine kinase but may indirectly impact angiogenic pathways involving ELTD1. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
A tyrosine kinase inhibitor that could indirectly affect ELTD1. | ||||||
Cediranib | 288383-20-0 | sc-483599 sc-483599A sc-483599B | 5 mg 10 mg 25 mg | $137.00 $220.00 $406.00 | ||
Inhibits VEGFR, potentially having downstream effects on ELTD1 activity. | ||||||